Literature DB >> 16509154

Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model.

Even Angell-Petersen1, Signe Spetalen, Steen J Madsen, Chung-Ho Sun, Qian Peng, Stephen W Carper, Mouldy Sioud, Henry Hirschberg.   

Abstract

OBJECT: Failure of treatment for high-grade gliomas is usually due to local recurrence at the site of resection, indicating that a more aggressive local therapy could be beneficial. Photodynamic therapy (PDT) is a local treatment involving the administration of a tumor-localizing photosensitizing drug, in this case aminolevulinic acid (ALA). The effect depends on the total light energy delivered to the target tissue, but may also be influenced by the rate of light delivery.
METHODS: In vitro experiments showed that the sensitivity to ALA PDT of BT4C multicellular tumor spheroids depended on the rate of light delivery (fluence rate). The BT4C tumors were established intracranially in BD-IX rats. Microfluorometry of frozen tissue sections showed that photosensitization is produced with better than 200:1 tumor/normal tissue selectivity after ALA injection. Four hours after intraperitoneal ALA injection (125 mg/kg), 26 J of 632 nm light was delivered interstitially over 15 (high fluence rate) or 90 (low fluence rate) minutes. Histological examination of animals treated 14 days after tumor induction demonstrated extensive tumor necrosis after low-fluence-rate PDT, but hardly any necrosis after high-fluence-rate treatment. Neutrophil infiltration in tumor tissue was increased by PDT, but was similar for both treatment regimens. Low-fluence-rate PDT administered 9 days after tumor induction resulted in statistically significant prolongation of survival for treated rats compared with nontreated control animals.
CONCLUSIONS: Treatment with ALA PDT induced pronounced necrosis in tumors only if the light was delivered at a low rate. The treatment prolonged the survival for tumor-bearing animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16509154     DOI: 10.3171/jns.2006.104.1.109

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  22 in total

1.  Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.

Authors:  Theresa M Busch; Hsing-Wen Wang; E Paul Wileyto; Guoqiang Yu; Ralph M Bunte
Journal:  Radiat Res       Date:  2010-09       Impact factor: 2.841

Review 2.  Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma.

Authors:  Harry Quon; Craig E Grossman; Jarod C Finlay; Timothy C Zhu; Clarice S Clemmens; Kelly M Malloy; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2011-06       Impact factor: 3.631

3.  Effect of chirality on cellular uptake, imaging and photodynamic therapy of photosensitizers derived from chlorophyll-a.

Authors:  Avinash Srivatsan; Paula Pera; Penny Joshi; Yanfang Wang; Joseph R Missert; Erin C Tracy; Walter A Tabaczynski; Rutao Yao; Munawwar Sajjad; Heinz Baumann; Ravindra K Pandey
Journal:  Bioorg Med Chem       Date:  2015-04-09       Impact factor: 3.641

4.  Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.

Authors:  Mukund Seshadri; David A Bellnier; Lurine A Vaughan; Joseph A Spernyak; Richard Mazurchuk; Thomas H Foster; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

5.  Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.

Authors:  Theresa M Busch; Xiaoman Xing; Guoqiang Yu; Arjun Yodh; E Paul Wileyto; Hsing-Wen Wang; Turgut Durduran; Timothy C Zhu; Ken Kang-Hsin Wang
Journal:  Photochem Photobiol Sci       Date:  2009-10-15       Impact factor: 3.982

6.  Photodynamic therapy of disseminated non-small cell lung carcinoma in a murine model.

Authors:  Craig E Grossman; Stephen Pickup; Amy Durham; E Paul Wileyto; Mary E Putt; Theresa M Busch
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

7.  Photodynamic opening of blood-brain barrier.

Authors:  Oxana Semyachkina-Glushkovskaya; Jürgen Kurths; Ekaterina Borisova; Sergei Sokolovski; Vanya Mantareva; Ivan Angelov; Alexander Shirokov; Nikita Navolokin; Natalia Shushunova; Alexander Khorovodov; Maria Ulanova; Madina Sagatova; Ilana Agranivich; Olga Sindeeva; Artem Gekalyuk; Anastasiya Bodrova; Edik Rafailov
Journal:  Biomed Opt Express       Date:  2017-10-17       Impact factor: 3.732

8.  Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors.

Authors:  Peter H Ahn; Harry Quon; Bert W O'Malley; Gregory Weinstein; Ara Chalian; Kelly Malloy; Joshua H Atkins; Thomas Sollecito; Martin Greenberg; Sally McNulty; Alexander Lin; Timothy C Zhu; Jarod C Finlay; Keith Cengel; Virginia Livolsi; Michael Feldman; Rosemarie Mick; Theresa M Busch
Journal:  Oral Oncol       Date:  2016-02-08       Impact factor: 5.337

9.  Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report.

Authors:  Walter Stummer; Tobias Beck; Wolfgang Beyer; Jan Hendrik Mehrkens; Andreas Obermeier; Nima Etminan; Herbert Stepp; Jörg-Christian Tonn; Reinhold Baumgartner; Jochen Herms; Friedrich Wilhelm Kreth
Journal:  J Neurooncol       Date:  2007-11-23       Impact factor: 4.130

10.  Disruption of the blood-brain barrier following ALA-mediated photodynamic therapy.

Authors:  Henry Hirschberg; Francisco A Uzal; David Chighvinadze; Michelle J Zhang; Qian Peng; Steen J Madsen
Journal:  Lasers Surg Med       Date:  2008-10       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.